News Algiax non-opioid drug works in chronic neuropathic pain A GABA-targeting drug developed by German Biotech Algiax has shown proof of concept in a chronic neuropathic trial trial.
News Vertex weakens after neuropathic pain trial reads out A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.
News Lilly adds to non-opioid pain pipeline with Confo deal Deal covers an AT2R inhibitor, a class that has been plagued by safety and efficacy issues.
News Lilly adds to pain pipeline with Asahi Kasei licensing deal US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t
Partner Content Partner Content Registration opens for SMi’s leading Pain Therapeutics Confe... Registration opens for Pain Therapeutics
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
